Jazz Pharmaceuticals Plc (JAZZ) Files Form 4 Insider Buying : Karen L. Smith Buys 580 Shares

Jazz Pharmaceuticals Plc (JAZZ): Karen L. Smith , Global Head of R&D and CMO of Jazz Pharmaceuticals Plc purchased 580 shares on Jul 13, 2016. The Insider buying transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $143.63 per share for a total value of $83,304.82 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $149.64 per share price.On Jun 15, 2016, Karen L. Smith (Global Head of R&D and CMO) purchased 557 shares at $149.61 per share price.Also, On May 26, 2016, Seamus Mulligan (director) sold 27,968 shares at $150.13 per share price.On May 17, 2016, Heather Ann Mcsharry (director) sold 697 shares at $145.20 per share price.

Jazz Pharmaceuticals plc – Ordinary Shares: On Monday, Jul 11, 2016 heightened volatility was witnessed in Jazz Pharmaceuticals plc – Ordinary Shares which led to swings in the share price. The shares opened for trading at $141.19 and hit $142.92 on the upside , eventually ending the session at $140.16, with a gain of 0.20% or 0.28 points. The heightened volatility saw the trading volume jump to 5,93,345 shares. The 52-week high of the share price is $194.73 and the company has a market cap of $8,469 M . The 52-week low of the share price is at $108.5.

Jazz Pharmaceuticals plc - Ordinary Shares Money Flow Index Chart

Company has been under the radar of several Street Analysts.Jazz Pharmaceuticals plc – Ordinary Shares is Initiated by Goldman to Buy and the brokerage firm has set the Price Target at $196. The Rating was issued on Jun 6, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Upgraded by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 193 from a previous price target of $137 .Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 11, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 168 from a previous price target of $162 .The Rating was issued on May 11, 2016.Jazz Pharmaceuticals plc – Ordinary Shares is Upgraded by Sun Trust Rbsn Humphrey to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Apr 25, 2016.

Leave a Reply

Jazz Pharmaceuticals plc - Ordinary Shares - Is it time to Sell?

Top Brokerage Firms are advising their investors on Jazz Pharmaceuticals plc - Ordinary Shares. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.